Eli Lilly Reports Positive Phase 2 Ulcerative Colitis Study Results
June 05 2018 - 11:14AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. (LLY) on Tuesday said patients in a Phase 2
study of mirikizumab in moderate-to-severe ulcerative colitis
achieved significantly greater rates of clinical remission at 12
weeks compared with placebo.
The Indianapolis drug maker said the results mark the first
safety and efficacy data for an IL-23p19 monoclonal antibody for
the treatment of moderate-to-severe ulcerative colitis, a chronic,
inflammatory bowel disease affecting the colon.
Eli Lilly said it will initiate a Phase 3 trial of mirikizumab
in moderate-to-severe ulcerative colitis this year. The drug is
already in a Phase 3 trial in moderate-to-severe plaque
psoriasis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2018 10:59 ET (14:59 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
